Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
Latest Information Update: 19 Oct 2022
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 17 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2020 Status changed from not yet recruiting to recruiting.
- 03 Nov 2020 Planned number of patients changed from 400 to 440.